WNK-IN-B, formerly known as Compound B, is a Wnk signalling inhibitor. WNK-IN-B is a cell-permeable diaminoacridine analogue that targets the CCT domain of SPAK and OSR1 via reversible binding It has been shown to selectively suppress hypotonic shock-induced WNK signaling pathway activation in mpkDCT and MOVAS (100 μM) cultures without affecting p38 MAPK phosphorylation. References: Mori T, Kikuchi E, Watanabe Y, Fujii S, Ishigami-Yuasa M, Kagechika H, Sohara E, Rai T, Sasaki S, Uchida S. Chemical library screening for WNK signalling inhibitors using fluorescence correlation spectroscopy. Biochem J. 2013 Nov 1;455(3):339-45. doi: 10.1042/BJ20130597. PubMed PMID: 23981180.

纯度：≥98%

CAS：332922-63-1